Autopsy report · NCT05120375

Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients in China

“Based on the disclosed global research data on the same target drugs, the company has carefully considered and decided to terminate the project to optimize the existing research pipeline.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 1 year 2 months before it stopped.
• 5 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Bio-Thera Solutions

Sponsor type

Industry

Conditions

Solid Tumor

Interventions

BAT6021

Participants

5

Sites

3

Countries

China

Trials that died the same way

• Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma
  “The main consideration is the allocation of company resources, We can only terminate this research.” (61% match in meaning)
• KSD-201 Treatment for Advanced Clear Cell Renal Cell Carcinoma: an Early Exploratory Clinical Study
  “Due to a strategic adjustment, the company has decided to terminate the project.” (60% match in meaning)
• Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
  “This study was terminated early due to the Sponsor's decision to discontinue development of the investigational drug and close the program.” (60% match in meaning)
• Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment
  “The study was terminated due to company restructuring and changes in drug development priorities.” (60% match in meaning)
• Pharmacokinetic Study of Artemether-lumefantrine and Amodiaquine in Healthy Subjects
  “The decision was made due to the expired investigational drug and regulatory changes by the Thai FDA, along with increased importation costs. The research team and investigational drug sponsor agreed to seek approval for early project termination.” (60% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.